Filter By Category
Archives
Share on -
ABELACIMAB
Generic Name: ABELACIMAB
ABSTRACT -
abelacimab is an antibody-derived API listed in the supplied A-series master. Product-specific target, construct, development status, and indications must be confirmed from the applicable regulatory record or clinical-trial protocol. This monograph avoids assigning an unverified molecular target.
DOSAGE –
Use the current locally approved prescribing information where a product is authorized. For investigational products, dose, route, schedule, premedication, and dose modifications must come only from the applicable clinical-trial protocol. No dose should be selected from this summary.
SIDE EFFECTS –
- Infusion- or injection-site reactions
- Headache or fatigue
- Fever or chills
- Rash or itching
- Infections or blood-count changes, depending on target
- Target-related immune or organ toxicity
ALLRGIC REACTIONS–
(These symptoms may indicate a serious allergic or infusion reaction and require medical attention.)
- Hives or a rapidly spreading rash
- Swelling of the face, lips, tongue, or throat
- Wheezing, breathing difficulty, or sudden dizziness
- Severe blistering, mucosal lesions, or anaphylaxis
DRUG INTERACTIONS -
-
-
- Other biologics or immunosuppressants may increase infection or immune-toxicity risk
- Live vaccines may be unsuitable during clinically significant immune suppression
- Formal metabolic interactions are generally limited but combination-regimen toxicity must be reviewed
-
PRECAUTIONS –
- Administer in a setting equipped to manage hypersensitivity
- Screen for infection and obtain target-appropriate baseline tests
- Monitor during and after administration according to the product protocol
- Follow pregnancy and contraception requirements
WARNINGS –
- Severe infusion reactions, anaphylaxis, infection, cytopenias, or immune-mediated toxicity can occur
- Do not infer dosing from another monoclonal antibody
Share on -
. Developed by